| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 2992 | 2013 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 1806 | 2017 |
| Lentivirus-delivered stable gene silencing by RNAi in primary cells SA Stewart, DM Dykxhoorn, D Palliser, H Mizuno, EY Yu, DS An, ... Rna 9 (4), 493-501, 2003 | 1562 | 2003 |
| Quantitative and stoichiometric analysis of the microRNA content of exosomes JR Chevillet, Q Kang, IK Ruf, HA Briggs, LN Vojtech, SM Hughes, ... Proceedings of the National Academy of Sciences 111 (41), 14888-14893, 2014 | 988 | 2014 |
| Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer A Kumar, I Coleman, C Morrissey, X Zhang, LD True, R Gulati, R Etzioni, ... Nature medicine 22 (4), 369-378, 2016 | 632 | 2016 |
| Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy JE Rosenberg, PH O’Donnell, AV Balar, BA McGregor, EI Heath, YY Evan, ... Journal of Clinical Oncology 37 (29), 2592, 2019 | 389 | 2019 |
| Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer CJ Kuo, F Farnebo, EY Yu, R Christofferson, RA Swearingen, R Carter, ... Proceedings of the National Academy of Sciences 98 (8), 4605-4610, 2001 | 364 | 2001 |
| Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer KN Chi, SJ Hotte, EY Yu, D Tu, BJ Eigl, I Tannock, F Saad, S North, ... Journal of clinical oncology 28 (27), 4247-4254, 2010 | 281 | 2010 |
| Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate CancerDasatinib in Metastatic CRPC EY Yu, G Wilding, E Posadas, M Gross, S Culine, C Massard, MJ Morris, ... Clinical Cancer Research 15 (23), 7421-7428, 2009 | 245 | 2009 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 220 | 2021 |
| The Role of Lineage Plasticity in Prostate Cancer Therapy ResistanceLineage Plasticity in Prostate Cancer Resistance H Beltran, A Hruszkewycz, HI Scher, J Hildesheim, J Isaacs, EY Yu, ... Clinical cancer research 25 (23), 6916-6924, 2019 | 184 | 2019 |
| Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019 VN Giri, KE Knudsen, WK Kelly, HH Cheng, KA Cooney, MS Cookson, ... Journal of Clinical Oncology 38 (24), 2798, 2020 | 176 | 2020 |
| Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer TK Choueiri, RW Ross, S Jacobus, U Vaishampayan, YY Evan, DI Quinn, ... Journal of clinical oncology 30 (5), 507, 2012 | 171 | 2012 |
| Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer MD Galsky, SK Pal, S Chowdhury, LC Harshman, SJ Crabb, YN Wong, ... Cancer 121 (15), 2586-2593, 2015 | 167 | 2015 |
| A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma M Hussain, S Daignault, N Agarwal, PD Grivas, AO Siefker‐Radtke, ... Cancer 120 (17), 2684-2693, 2014 | 118 | 2014 |
| Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis T Koreckij, H Nguyen, LG Brown, EY Yu, RL Vessella, E Corey British journal of cancer 101 (2), 263-268, 2009 | 112 | 2009 |
| A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy K Zargar-Shoshtari, H Zargar, Y Lotan, JB Shah, BW Van Rhijn, ... The Journal of urology 195 (1), 53-59, 2016 | 100 | 2016 |
| A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer MT Schweizer, K Haugk, JS McKiernan, R Gulati, HH Cheng, JL Maes, ... PloS one 13 (6), e0198389, 2018 | 99 | 2018 |
| A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors CS Higano, EY Yu, SH Whiting, MS Gordon, P LoRusso, F Fox, TL Katz, ... Journal of Clinical Oncology 25 (18_suppl), 3505-3505, 2007 | 98 | 2007 |
| A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer … KN Chi, EY Yu, C Jacobs, J Bazov, C Kollmannsberger, CS Higano, ... Annals of Oncology 27 (6), 1116-1122, 2016 | 97 | 2016 |
